References
1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328-57. DOI: 10.1002/hep.29367
2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59(6): 1121-40. DOI: 10.1007/s00125-016-3902-y
3. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11(1):1-16. DOI: 10.1016/j.cld.2007.02.009
4. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:76-84. DOI: 10.1002/hep.28431
5. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149(2):367-78. DOI: 10.1053/j.gastro.2015.04.005.
6. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771. DOI: 10.1136/bmj.d7771
7. Yoo J, Cho IJ, Jeong IK, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation. Toxicol Appl Pharmacol 2018;360:18-29. DOI: 10.1016/j.taap.2018.09.032
8. Zhu W, Feng PP, He K, et al. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet. Biochem Biophys Res Commun 2018;505(2):523-9. DOI: 10.1016/j.bbrc.2018.09.134
9. Yamamoto T, Nakade Y, Yamauchi T, et al. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World J Gastroenterol 2016;22(8):2512-23. DOI: 10.3748/wjg.v22.i8.2512
10. Cuthbertson DJ, Irwin A, Gardner CJ, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 2012;7(12):e50117. DOI: 10.1371/journal.pone.0050117
11. Kenny PR, Brady DE, Torres DM, et al. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 2010;105(12):2707-9. DOI: 10.1038/ajg.2010.363
12. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097. DOI: 10.1371/journal.pmed.1000097
13. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Internet]. [cited 2011 Mar 20]. Available from: http://handbook.cochrane.org.
14. Wan X, Wang WQ, Liu JM, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
15. Yan J, Yao B, Kuang H, et al. Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD. Hepatology 2019;69(6):2414-2426. DOI: 10.1002/hep.30320
16. Feng WH, Bi Y, Li P, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. J Diabetes Investig 2019;10(2):399-407. DOI: 10.1111/jdi.12888
17. Feng WH, Gao C, Bi Y, Li P, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes 2017;9(8): 800-809. DOI: 10.1111/1753-0407.12555
18. Fan H, Pan QR, Xu Y, et al. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metab 2013;57(9):702-8. DOI: 10.1590/s0004-27302013000900005
19. Shao N, Kuang HY, Hao M, et al. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev 2014;30(6):521-9. DOI: 10.1002/dmrr.2561
20. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet 2016;387(10019):679-90. DOI: 10.1016/s0140-6736(15)00803-x
21. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016;64(2):399-408. DOI: 10.1016/j.jhep.2015.08.038
22. Khoo J, Hsiang J, Taneja R, et al. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. Diabetes Obes Metab 2017;19(12):1814-17. DOI: 10.1111/dom.13007
23. Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007;22(6):775-7. DOI: 10.1111/j.1440-1746.2007.05002.x
24. Seko Y, Sumida Y, Tanaka S, et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 2015;45(10):E53-61. DOI: 10.1111/hepr.12456
25. Dong Y, Lv Q, Li S, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017;41(3):284-95. DOI: 10.1016/j.clinre.2016.11.009
26. Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2016;31(1):23-31. DOI: 10.1111/jgh.13026
27. Patel SA, Hoehn KL, Lawrence RT, et al. Overexpression of the adiponectin receptor AdipoR1 in rat skeletal muscle amplifies local insulin sensitivity. Endocrinology 2012;153(11):5231-46. DOI: 10.1210/en.2012-1368
28. Lara-Castro C, Luo N, Wallace P, et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006; 55(1): 249-59
29. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42(5):987-1000. DOI: 10.1002/hep.20920
30. Wang XC, Zhan XR, Li XY, et al. Identification and validation co-differentially expressed genes with NAFLD and insulin resistance. Endocrine 2015;48(1):143-51. DOI: 10.1007/s12020-014-0247-5
31. Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010;51(5):1584-92. DOI: 10.1002/hep.23569
32. Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43(1):173-81. DOI: 10.1002/hep.21006
33. Ben-Shlomo S, Zvibel I, Shnell M, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2011;54(6):1214-23. DOI: 10.1016/j.jhep.2010.09.032
34. Gupta NA, Kolachala VL, Jiang R, et al. The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol 2012;181(5):1693-701. DOI: 10.1016/j.ajpath.2012.07.015
35. Sharma S, Mells JE, Fu PP, et al. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 2011;6(9):e25269. DOI: 10.1371/journal.pone.0025269